Akela Pharma Revenue

Pharmaceutical Manufacturing • United States • 11-20 Employees

Akela Pharma revenue & valuation

Annual revenue	$15,000,000
Revenue per employee	$883,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$48,000,000
Total funding	No funding

Key Contact at Akela Pharma

Jeff La Force

Director Of Financial Reporting

Company overview

Headquarters	United States
Website	akelapharma.com
NAICS	3254
SIC	2834, 283
Founded	1996
Employees	11-20
Socials

Akela Pharma Email Formats

Akela Pharma uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About Akela Pharma

We are an integrated product development company primarily focused on therapeutics for pain utilizing our proprietary drug delivery technologies. Our lead product candidate is Fentanyl TAIFUN®, a fentanyl formulation specifically designed to be delivered with our TAIFUN® Multi-Dose Inhaler. We are developingFentanyl TAIFUN® as a rapid-acting inhaled opioid analgesic for treatment of break-through cancer pain. In June 2007, we entered into an exclusive license and development agreement with Janssen Pharmaceutica N.V. with respect to the continuing development and commercialization of Fentanyl TAIFUN®. We believe, based upon the results of our clinical trials to date, that our Fentanyl TAIFUN® product candidate, if approved by regulatory agencies, will deliver much faster onset of pain relief from break-through cancer pain at lower dosages than other non-injectable products currently indicated for break-through cancer pain. Break-through cancer-related pain has a severe impact on a patient's quality of life and can occur even if the individual is taking chronic pain medication on a regular basis. Break-through pain is a common component of chronic pain and is characterized by its rapid onset, intensity and relatively short duration. These intermittent flare-ups of intense pain "break-through" the effect of chronic pain medication. We believe currently available therapeutics targeted at break-through cancer pain are inadequate because of their higher dosage of fentanyl and comparatively longer time to onset.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

Manager

Director

Employees by Department

Akela Pharma has 7 employees across 4 departments.

Departments

Number of employees

Funding Data

Akela Pharma has never raised funding before.

Frequently asked questions

Akela Pharma is located in US.

Akela Pharma generates an estimated annual revenue of $15,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Akela Pharma has an estimated valuation of $48,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Akela Pharma was founded in 1996, making it 30 years old. The company has established itself as a significant player in its industry over this time.

Akela Pharma has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Akela Pharma

Jeff La Force

Director Of Financial Reporting

4.8

40,000 users